AstraZeneca — full event log

GRI 2-5 references external assurance disclosed in Annual Report 2025 pp. 83, 85, 220-221. Specific assurance level not detailed in this index.

sustainability_report p.4

AstraZeneca updated its 2024 double materiality assessment in 2025; the list of material topics in the GRI index reflects this update.

sustainability_report p.4

GRI 2-4 indicates restatements of information are documented in Annual Report 2025 p. 43 and Sustainability Data Reporting Criteria 2025 p. 34. Specific restatements not detailed in this index document.

sustainability_report p.4

AstraZeneca developing next-generation respiratory inhaler propellant with near-zero global warming potential (99.9% lower than today's medicines). First launches anticipated from 2025 subject to regulatory approvals.

sustainability_report p.16

This document is a SASB and GRI content index that points to the AstraZeneca Annual Report 2025 and Sustainability Data Annex 2025 for actual metric values. No numeric metrics are disclosed in this index document itself.

sustainability_report p.2

Transitioning pressurised Metered Dose Inhalers (pMDIs) to a next-generation propellant with near-zero Global Warming Potential. First approval received in UK in May 2025 (Trixeo Aerosphere); filings in EU and China; aim to transition wider pMDI portfolio by 2030. At Dunkirk, France, F-gas emissions from manufacturing are eliminated via vacuum purging of empty canisters and cryogenic capture/liquefaction for incineration or recycling. Use-of-sold inhaler propellants are a material part of AstraZeneca's product-emissions footprint.

sustainability_report p.11

Total waste reduced 13% vs 2015. At Coppell, Texas, a circularity programme repurposes ~11,915 metric tons/year of filtered material from a high-volume sachet production process into concrete-industry feedstock to avoid landfill. 96% of paper-based product packaging materials used in 2024 came from sustainable sources. Lab waste reductions through Green Labs programme (lab plastics, gloves recycling; reduced solvent use).

sustainability_report p.20

More than 1,000 suppliers have committed to setting science-based targets — around one in 10 of all companies signed up to SBTi are AstraZeneca partners. Suppliers are supported through innovative decarbonisation solutions including the Energize programme. SMI-led joint China renewable PPA enabled 9 suppliers to procure ~225 GWh/year of wind and solar, with sector-wide annual savings of ~250,000 tCO2e.

sustainability_report p.10

By 2025 AstraZeneca aims to have 100% renewable electricity consumption at sites worldwide and 100% electric road fleet where technically feasible, reduce total energy consumption from sites by 10% from 2015, and double energy productivity at sites from 2015.

sustainability_report p.15

Starting in 2024, AstraZeneca is investing $5 million per year to fund nature restoration and water stewardship projects to address shared water challenges in operating communities.

sustainability_report p.27

AstraZeneca aims to halve its entire value chain footprint by 2030 and reduce absolute Scope 3 GHG emissions by 90% vs 2019 baseline by 2045 to become science-based net zero, in alignment with the SBTi Corporate Net-Zero Standard. Investing more than $1 billion to support transition.

sustainability_report p.9

63% of AstraZeneca's car fleet are battery electric vehicles as of 2024, with a target of 100% electric road fleet where technically feasible by 2025.

sustainability_report p.7

Scope 1+2 emissions reduced 77.5% vs 2015 while doubling the business. Largest site Södertälje, Sweden (40% of global production volume) delivered a 98% Scope 1+2 reduction vs 2015 baseline 18 months ahead of its 2026 target; all Swedish sites including Gothenburg R&D have hit the 98% milestone. Newest sites designed to Ambition Zero Carbon Scope 1+2 targets from day one (e.g. DISC, Cambridge).

sustainability_report p.17

$400 million invested in AZ Forest, a global reforestation and biodiversity programme co-designed with ecological experts, indigenous peoples and local communities. Over 40 million trees planted across six continents since 2020. Projects use diverse, locally appropriate native species; local tree projects monitored for an average of three years and large-scale reforestation projects for at least 10 years. Removals are framed as nature-based; the report does not discuss durable engineered removals (DAC/BECCS). A pilot carbon capture component is featured at the Future Biogas Moor Bioenergy biomethane plant in the UK.

sustainability_report p.22

Young Health Programme is aligned to the United Nations' Sustainable Development Goal 3.4, which aims to prevent the most common NCDs such as cancer, diabetes, heart disease, and respiratory disease.

sustainability_report p.31

In 2024, AstraZeneca became a founding partner of the Climate Group's new 24/7 Carbon-Free Coalition, aiming to operate on 100% carbon-free electricity, 24 hours per day, 7 days per week by matching electricity demand with carbon-free generation where and when consumption occurs.

sustainability_report p.18

By 2030, AstraZeneca aims to positively impact 1 billion people, including 400 million people from underserved groups, and to make AstraZeneca medicines available in more than 125 countries.

sustainability_report p.24

In December 2024, AstraZeneca became the first organisation globally of any sector to achieve the new My Green Lab 2.0 certification and the first organisation to certify every operational site at Green level. 129 lab spaces certified across 19 countries; 91 at Green level.

sustainability_report p.18

Following Climate Group's RE100 criteria, AstraZeneca has reached 97% certified renewable electricity across operations and aims for 100% by 2025. Internal standards focus on additionality (new renewable capacity), geographic relevance (PPAs displacing fossil energy close to consumption) and temporal relevance (24/7 matching). Key deals include a 200 GWh/year, 10-year wind PPA with Statkraft in Sweden; a 15-year unsubsidised biomethane agreement with Future Biogas (Moor Bioenergy, Lincolnshire) for UK R&D and manufacturing heat displacing ~18,000 tCO2e/year; Vanguard Renewables RNG for all US sites by end of 2026; biomethane-based steam at Wuxi, China; and a SMI-led joint renewable PPA in China enabling 9 suppliers to access ~225 GWh/year (industry savings ~250,000 tCO2e/year). Founding partner of Climate Group 24/7 Carbon-Free Coalition (2024).

sustainability_report p.16

AZ Forest programme aims to plant and monitor 200 million trees across six continents by 2030, restoring over 100,000 hectares of land. $400 million invested. Over 40 million trees planted since 2020.

sustainability_report p.9

AstraZeneca quantifies emissions of suboptimal disease management — e.g. poorly-controlled COPD patients see ~50% higher annual care-related GHG emissions vs well-controlled patients. Early detection programmes (CKD screening targeting 140 million people; aim to reduce kidney failure cases 20% by end-2025) and the CARESA modelling tool (open-access from early 2025) help health systems decarbonise care pathways. Electronic Product Information (ePI) could save 50,000 tCO2e and 500,000 trees per year if rolled out across AstraZeneca medicines.

sustainability_report p.13

Founding member of Energize (Schneider Electric + 19 pharma firms enabling supplier PPAs — 286 AZ suppliers registered; 2 TWh first PPA cohort announced Nov 2022). Joined Activate Programme for API supply-chain decarbonisation. SMI Health Systems Task Force signed industry-first renewable power agreement in China (Jan 2024) saving ~120 kt CO2e/yr. Target: 95% of purchased-goods/capital-goods supplier spend with verified SBTs by 2025 (29% in 2023).

sustainability_report p.19

AstraZeneca is expanding renewable energy access through innovative partnerships: in the US with Vanguard Renewables to transform food/farm waste into renewable natural gas (RNG) supplying all US R&D and manufacturing sites by 2026; in the UK with Future Biogas establishing the first unsubsidised industrial-scale biomethane supply for Macclesfield, Cambridge, Luton and Speke sites; and in China with China Resources Gas, plus a multi-party agreement with Envision Energy targeting ~120,000 tCO2e annual savings. Founding member of 'Energize' coalition with Schneider Electric and 19 healthcare companies, with 286 AZ suppliers registered to buy 2TWh of renewable electricity since 2022.

sustainability_report p.20

35% of AstraZeneca's road fleet are battery electric vehicles (vs 2015 baseline). Continued shift away from internal combustion supports Scope 1 reductions.

sustainability_report p.7

Green Labs programme integrates sustainability standards into research processes with 4,000+ colleagues optimising lab practices. Focus on cold storage management, switching off equipment, eco-friendly waste disposal, recycling of plastics/gloves, and reducing raw material/solvent use. 100+ labs certified by My Green Lab; 41 at the highest Green level.

sustainability_report p.15

EV100 commitment: 100% electric road fleet where technically possible by end of 2025. BEVs reached 35% of fleet in 2023 (up from 10% in 2022, 2% in 2021). Hybrid + PHEV represent additional 40%. Road fleet Scope 1 emissions fell from 92.5 ktCO2e (2015) to 47.8 ktCO2e (2023).

sustainability_report p.33

With 97% of emissions in Scope 3, AstraZeneca targets 95% of key suppliers/partners by spend to have science-based targets by end of 2025. AZ suppliers represent 12% of all companies taking action with SBTi (as of May 2024). Collaborating via 'Energize' (renewable power access) and 'Activate' (API supply chain decarbonisation) industry programmes.

sustainability_report p.19

Tackles ~20% of Scope 3 footprint (Cat 11 use of sold products). Developing pMDI with HFO-1234ze(E) propellant (near-zero GWP) to replace high-GWP HFC propellants currently used in respiratory inhalers. 2023 milestones: Phase III investment decisions, harmonised global development programme, pivotal study readouts, regulatory filing studies initiated. Launch targeted by 2025.

sustainability_report p.20

Cat 6 business travel emissions rose to 155 ktCO2e in 2023 (from 84 kt in 2021 post-COVID rebound) but remain below 2019 baseline of 327 kt. 32% of business-travel supplier spend now covered by verified SBTs (up from 14% in 2022); targeting 50% by 2025.

sustainability_report p.33

Reducing Cat 4 upstream transport emissions by shifting from air to sea and rail freight. 73% of tonne.km and 64% of volume moved by sea/rail in 2023. 27% of category-4 supplier spend now covered by verified SBTs (up from 19% in 2022).

sustainability_report p.34

Reduce absolute Scope 1 and 2 GHG emissions by 98% by 2026 from 2015 base year; reduce absolute Scope 3 by 50% by 2030 and 90% by 2045 from 2019 base year.

sustainability_report p.32

95% of suppliers by spend (purchased goods, capital goods) and 50% (upstream transport, business travel) to have validated science-based targets by 2025.

sustainability_report p.32

Water reduction target on track: 19.5% reduction achieved vs 20% by 2025 target.

sustainability_report p.23

Target to reach gender equality in management positions by 2025; 50.1% senior middle management roles held by women in 2023.

sustainability_report p.39

Scope 1, energy and waste data restated due to a site divestment and change in GWP values applied to F-gas calculations.

sustainability_report p.32

AstraZeneca was one of the first seven companies to have its net-zero targets verified under the Science-Based Targets Initiative's Net-Zero Corporate Standard.

sustainability_report p.19

Goal that by end of 2025, 95% of key suppliers and partners by spend will have science-based targets. 286 AstraZeneca suppliers registered with Energize to buy 2TWh of renewable electricity since 2022.

sustainability_report p.19

AstraZeneca on track to reduce Scope 1 and 2 GHG emissions by 98% by 2026 (vs 2015 baseline); 67.6% reduction already achieved by end 2023. $1B investment in 'Ambition Zero Carbon' decarbonisation strategy.

sustainability_report p.18

AstraZeneca committed to be an Early Adopter of the Taskforce on Nature-related Financial Disclosures (TNFD) framework.

sustainability_report p.24

Use-of-sold emissions from MDIs are a major Scope 3 driver. Developing next-gen inhaler propellant with near-zero GWP (99.9% lower), non-persistent, non-bioaccumulative. First launches anticipated from 2025 subject to regulatory approvals.

sustainability_report p.16

Transition to paperless product information leaflets. ~100 billion paper leaflets are printed annually for medicine packs industry-wide. In Maihara, Japan site achieved 100% switch to digital ePI in one year, eliminating 30m sheets of paper, 180t of waste, and 154t CO2 emissions.

sustainability_report p.16

AstraZeneca aims to halve absolute Scope 3 GHG emissions by 2030 and achieve a 90% reduction by 2045, with carbon negative for residual emissions by 2030.

sustainability_report p.18

$400 million commitment to plant and maintain 200 million trees across six continents by 2030 and restore over 100,000 hectares of land. 19m+ trees planted to date across Australia, Brazil, Ghana, India, Indonesia, Rwanda, US and UK.

sustainability_report p.25

AstraZeneca's $400M AZ Forest commitment aims to plant and maintain 200 million trees across six continents by 2030, restoring 100,000+ hectares. 19m+ trees planted across Australia, Brazil, Ghana, India, Indonesia, Rwanda, US and UK. Reforestation is the primary mechanism to compensate residual emissions and achieve 'carbon negative' status by 2030. Projects co-designed with local communities, with monitoring of 3 years (local) and 10+ years (large-scale) for survival.

sustainability_report p.25

Decarbonising energy-intensive manufacturing/R&D heat via biomethane (UK Future Biogas), RNG from food/farm waste (US Vanguard), and renewable gas (China Resources). The China partnership alone targets up to 80% reduction in Scope 1+2 emissions in China. 5 facilities (Lomas Verdes, Cotia, Nijmegen, Cairo, Cikarang) have already delivered a sustained 98% reduction in Scope 1+2.

sustainability_report p.20

Achieved My Green Lab Certification in 100+ lab spaces globally, with 41 labs awarded highest-level Green certification. First organisation in the Americas to achieve Green certification in manufacturing/supply. Awarded 'Sustainable Lab of the Year' by Lab Innovations in 2023.

sustainability_report p.15

Expanded AZ Forest programme to $400m investment to plant and maintain 200 million trees by 2030. Committed to TNFD early adopter status and to set SBTN water and biodiversity targets by 2025.

sustainability_report p.23

Scope 3 historic figures restated due to methodology changes to improve data quality. Primary data share in Scope 3 increased from 38% (2022) to 52% (2023).

sustainability_report p.33

Reports alignment with SDGs 3 (Good health), 5 (Gender equality), 6 (Clean water), 7 (Affordable and clean energy), 8 (Decent work), 12 (Responsible consumption), 13 (Climate action), 15 (Life on land), 17 (Partnerships).

sustainability_report p.4

AZ reached 95% renewable electricity in 2023 (99% imported electricity from certified renewable sources, with shortfall due to Russia). Targets 100% renewable energy by end of 2025. Strategy emphasises additionality, geographic relevance and temporal relevance. Signed 10-year PPA with Statkraft for 200 GWh/yr Swedish wind (~80% of Gothenburg/Södertälje needs). Invested $19.4m in on-site solar PV at nine sites in seven countries (32 GWh capacity). 15-year Future Biogas agreement in UK and Vanguard Renewables RNG deal in US (up to 190 GWh/yr, ~36% of global gas).

sustainability_report p.18

AZ Forest expanded in 2023 to a $400m commitment to plant and maintain 200 million trees by 2030 across 100,000+ hectares in Australia, Brazil, Ghana, India, Indonesia, Rwanda, UK and US; 19.9m trees planted to date using 300+ species. Projects co-designed with European Forest Institute and Circular Bioeconomy Alliance under science-based regenerative-landscape principles. Removals used to compensate for residual Scope 1&2 footprint within Ambition Zero Carbon waterfall (13 ktCO2e shown as 'Carbon Removal' in 2023 chart).

sustainability_report p.23

Eliminate-reduce-substitute hierarchy applied to site fossil gas use. US sites to receive renewable natural gas from Vanguard Renewables (up to 190 GWh/yr by 2026, 36% of global gas). UK sites covered by 15-year Future Biogas biomethane agreement (100+ GWh, 19% of global gas). Heat pumps and electric boilers prioritised where feasible. Site energy Scope 1 fell from 167 ktCO2e (2015) to 93 ktCO2e (2023).

sustainability_report p.18

For the seventh consecutive year, AstraZeneca achieved a double A-rating from CDP for Climate Change and Water Security. CDP Forest score: B for timber, B for palm oil, C for cattle.

sustainability_report p.26

Targeting 15% of Scope 3 footprint via product innovation. Partnership with Honeywell announced 2022 to develop next-generation pressurised metered-dose inhaler using HFO-1234ze, a near-zero GWP propellant; first launch targeted by 2025. Use-of-sold-products footprint targeted for 95% reduction by 2045. F-gas management programme initiated; reduce and capture F-gas emissions from production of respiratory medicines.

sustainability_report p.21

By end 2025, 95% of spend in Scope 3 cat 1 (purchased goods) and cat 2 (capital goods) to be with suppliers having SBTs aligned to <1.5°C (12% achieved in 2022); 50% of spend in cat 4 (upstream transport) and cat 6 (business travel) likewise. Joined Energize (Schneider Electric + 16 pharma sponsors) to give suppliers access to renewable PPAs — 210+ AZ suppliers registered, 54% undertook Scope 3 training. 480+ suppliers (58% of in-scope spend) report GHG via CDP Supply Chain programme.

sustainability_report p.22

Business air travel emissions in 2022 were 53% below the 2019 baseline (baseline of 327 ktCO2e for cat 6 business travel). Combined with freight is included in target of 50% supplier spend by 2025 covering transportation, distribution and business travel having SBTs, and 46% GHG reduction by 2030.

sustainability_report p.21

Achieved 74% by tonne.km transition of freight from air to sea and rail by 2022 — addressing Scope 3 cat 4 (upstream transportation and distribution), which had a 2019 baseline of 248 ktCO2e. Target 46% GHG reduction in upstream transportation and business travel by 2030.

sustainability_report p.21

AstraZeneca is committed to 100% renewable energy by end of 2025 (RE100). In 2021 it transitioned to 100% imported electricity from certified renewable sources via EACs (same country, same year); this fell to 99% in 2022 as Russia certs were unavailable. Targeting majority of electricity in Sweden, UK, US via new PPAs. Committed $23.1m over 2022-2024 to on-site solar PV at ten sites in eight countries (27 GWh once operational, ~3% of global electricity use). Joined Eurelectric 24/7 taskforce for temporal matching. For heat: UK biomethane partnership with Future Biogas (signed 2021), exploring RNG/biomethane for US sites, electrification via heat pumps and electric boilers.

sustainability_report p.22

Signed EV100 commitment to maximise EV transition by 2025. By 2022: 10% EV, 63% green fleet (EV, hybrid or plug-in hybrid); first market has reached 100% EV. Transition impeded by lack of vehicles, EV infrastructure and supply chain issues in some markets.

sustainability_report p.21

Natural Resource Efficiency Fund has invested ~$150m since 2015 in environmental efficiency innovations; $26.6m further invested in 2022 across 31 new projects ($21m on energy efficiency and on-site solar PV). 14.4% absolute energy reduction since 2015 baseline; EP100 target to double energy productivity by 2025. Substituting natural gas with renewable heat sources; heat pumps and electric boilers prioritised.

sustainability_report p.22

AstraZeneca's compensation hierarchy is Eliminate → Reduce → Substitute → Compensate. Residual Scope 1&2 emissions from 2026 will be compensated through high quality removals using Bioenergy with Carbon Capture and Storage (BECCS). For the 2030 carbon-negative value chain goal, residual emissions will be compensated through high quality nature-based solutions, anchored by the AZ Forest 50-million-tree programme (10.5 million planted since 2020 across Australia, Indonesia, Ghana, US, UK). Aims to remove more CO2e than emitted from 2030 to become carbon negative.

sustainability_report p.21

In 2022, Alexion (Rare Disease therapy area) was integrated into Product Sustainability programmes including first LCA studies. Workforce safety reported separately for Alexion (6% of total workforce).

sustainability_report p.23

From 2022, AstraZeneca cannot purchase renewable electricity certificates for operations in Russia, leading to an increase in reported Scope 2 emissions. Renewable electricity share dropped from 100% (2021) to 99% (2022).

sustainability_report p.20

Share of primary data in Scope 3 reporting increased to 38% in 2022, improving accuracy of value-chain emissions accounting. LCA scope expanded to include Rare Disease (Alexion) products for first time.

sustainability_report p.21

Commitment to plant and maintain 50 million surviving trees by 2025; over 10.5 million trees planted since 2020 across Australia, Indonesia, Ghana, US and UK. Building risk-based approach to assess nature impacts in supply chain in preparation for TNFD reporting. Partnership with WWF Sweden on water stewardship under Alliance for Water Stewardship Standard.

sustainability_report p.26

AstraZeneca was one of the first seven companies to have net-zero Scope 1-3 targets verified under the Science-Based Targets Initiative's Net-Zero Corporate Standard. Targets: Scope 1&2 -98% by 2026 from 2015 base; Scope 3 -50% by 2030 and -90% by 2045 from 2019 base.

sustainability_report p.20

In 2022, AstraZeneca increased the ambition of its water use target, now aiming to reduce water use by 20% from 2015 baseline levels (previously a lower target).

sustainability_report p.25

Maps progress and metrics to UN Sustainable Development Goals: SDG 3 (Good Health), 5 (Gender Equality), 6 (Clean Water), 7 (Affordable Clean Energy), 8 (Decent Work), 12 (Responsible Consumption), 13 (Climate Action), 15 (Life on Land), 17 (Partnerships).

sustainability_report p.7

CDP-worldwide double A rating for climate change and water security for the sixth consecutive year. Also first published CDP Forests rating: C.

sustainability_report p.26

AstraZeneca expanded its Ambition Zero Carbon strategy to include a net zero emissions target across the value chain by 2045, verified by SBTi under their new Corporate Net Zero Standard. One of first seven companies worldwide to have net zero Scope 1-3 targets verified. Also targets 50% Scope 3 reduction by 2030 from 2019 baseline, and 98% Scope 1+2 reduction by 2026 from 2015 baseline.

sustainability_report p.3

Alexion acquired in 2021. Reporting boundary expanded to include Alexion across all scopes (1, 2, 3) and integrated to previous years' reporting. Affects 2021 data for emissions, water, waste, and workforce metrics.

sustainability_report p.35

Scope 1, 2 and 3 emissions from Alexion acquired during 2021 - reporting boundary expansion to include the acquired business, calculate emissions across all scopes consistently, and integrate to previous years reporting.

sustainability_report p.35

AstraZeneca evaluates contribution to UN SDGs by connecting them to targets, annual progress, material focus areas. Highlighted SDGs: 3 (Good health), 5 (Gender equality), 6 (Clean water), 7 (Affordable & clean energy), 8 (Decent work), 12 (Responsible consumption), 13 (Climate action), 15 (Life on land), 17 (Partnerships).

sustainability_report p.7

AZ Forest commitment to plant and maintain 50 million trees worldwide by end of 2025, partnering with One Tree Planted. 3,430,061 trees planted since 2020. Active in Indonesia (20m), Australia (25m), UK (1m+). Supports WEF 1t.org platform.

sustainability_report p.22

Introduced water stewardship pilot focused on six prioritised sites in water-scarce areas across five countries. Will set locally-appropriate water targets in 2022 and long-term contextual targets by 2025. Supported by WWF Sweden partnership and WWF water risk filter tool.

sustainability_report p.25

Flagship programme commits to 98% Scope 1+2 reduction by 2026 (2015 baseline), 50% Scope 3 by 2030 (2019 baseline), 90% Scope 3 by 2045. First pharma to join all 3 of Climate Group's RE100, EV100, EP100. Targets SBTi-verified.

sustainability_report p.20

Launched supplier diversity programmes in Australia, New Zealand, Poland in 2021, bringing total to 8 countries (US, Puerto Rico, Brazil, UK, South Africa + 3 new). 20% increase in spend with diverse suppliers in 2021.

sustainability_report p.32

Plans to compensate for any residual Scope 1 and 2 emissions through high quality removals using BECCS (bioenergy with carbon capture and storage). The Future Biogas partnership in UK will capture biogenic CO2 from anaerobic digestion of energy crops and put it into permanent storage in UK North Sea rock formations. AZ Forest plants 50 million trees worldwide by 2025 (3.43M planted since 2020) for nature-based sequestration. Target to be carbon negative from 2030 by removing more CO2 from the atmosphere than emitted.

sustainability_report p.21

Partnership with Future Biogas in UK to build a new renewable energy plant generating up to 125 GWh biomethane substituting natural gas, with BECCS for permanent CO2 storage. Targets transitioning 100% self-generated and imported heating/cooling to renewables. Also reducing and capturing F-gas emissions from respiratory medicine manufacturing.

sustainability_report p.22

Member of Climate Group's EV100. In 2021: 2% electric vehicles; 57% green fleet (EV, hybrid or plug-in hybrid). Target fully electric vehicle fleet by 2025. Transition management cars to electric vehicles; minimise business air travel and switch from air freight to sea and rail freight.

sustainability_report p.21

Alexion acquired in 2021; historic compliance and safety data restated to incorporate Alexion.

sustainability_report p.36

Internal Product Sustainability Index (PSI) launched 2021, with pilot across 4 brands. Targets 90% of API syntheses meeting resource efficiency targets at launch by 2025. Achieved 14% PMI reduction across late stage project portfolio in 2021. Life cycle assessments identify CO2 hotspots in clinical trials (travel, samples, waste) and solvents (>70% of API footprint).

sustainability_report p.23

Top 250 suppliers invited to participate in CDP Supply Chain Programme; >70% disclosed climate data in 2021. Launched Energize programme at COP26 with industry peers and Schneider Electric to provide suppliers with access to renewable power at scale. Target 95% of suppliers by spend (purchased goods/services + capital goods) covered by approved SBTs by 2025; 50% covered for transportation/distribution/business travel. In 2021, 7% of spend with companies with approved SBTs.

sustainability_report p.22

In 2021 AstraZeneca transitioned to 100% imported electricity from certified renewable sources. Committed $20M over 2020-2023 to on-site solar PV at six sites in five countries, expected total output ~14,400 MWh (~2% of imported electricity needs). Includes $3.5M for a 2MW seven-acre solar field at Mount Vernon, Indiana (10-15% of site demand). Aiming to meet majority of electricity needs in primary consumption locations (Sweden, US, UK) through power purchase agreements (PPAs) by end of 2025. Member of RE100.

sustainability_report p.22

Partnership with Honeywell to develop and commercialise next-generation pressurised metered-dose inhalers using HFO-1234ze, a near-zero global warming potential propellant. Positive Phase I trial results in 2021. Target to launch first next-generation inhaler with low/near-zero GWP propellants by 2025. Expected to reduce patient use-of-sold-products emissions by 95% by 2030.

sustainability_report p.21

$130M invested since 2015 in natural resource efficiency projects, including 56 new projects and $30M spent in 2021; $25M allocated for 2022. Targets doubling energy productivity from 2015 baseline (EP100). Achieved 9% reduction in energy consumption in 2021.

sustainability_report p.19

Downstream transportation accounts for 4.8% of Scope 3. Achieved 29% reduction in freight and logistics emissions since 2015. Monitoring 1,300+ global logistics routes.

sustainability_report p.35

Use of sold products (primarily pMDI patient use) accounts for 12.5% of Scope 3. Addressed via next-generation low-GWP inhalers and research showing improved asthma management reduces reliever overuse — up to 250,000 tonnes CO2e per year in UK alone tied to reliever overuse.

sustainability_report p.36

Fuel combustion is 54.5% of Scope 1+2 — the largest operational source. Joined Renewable Thermal Collaborative in 2020. Clean heat studies underway for UK and US portfolios considering green gas to electrification of heat. Doubling energy productivity by 2025 under EP100.

sustainability_report p.37

Fleet accounts for 17% of Scope 1+2 emissions. Committed to EV100 — switch to fully electric vehicle fleet by 2025. EV readiness study completed for all markets with fleet presence; countries identified as 'EV ready'.

sustainability_report p.36

Site F-Gas and solvents account for 19.2% of Scope 1+2. Pressurised metered-dose inhalers (pMDIs) use HFC propellants subject to Kigali Amendment phase-down. AstraZeneca committed to launch next-generation inhaler with near-zero GWP propellant by 2025 (90-99% reduction).

sustainability_report p.36

AZ Forest is a global reforestation initiative to plant 50 million trees worldwide by 2025 as the primary nature-based solution to address residual emissions on the path to carbon negative value chain by 2030. More than 337,000 trees planted in Indonesia and Australia in 2020. Trees naturally remove CO2 while supporting disease prevention and biodiversity. AstraZeneca commits to no reliance on offset schemes for its 2025 operations target.

sustainability_report p.37

Committed to launch next-generation pMDI inhaler with near-zero GWP propellant by 2025 (90-99% lower GWP).

sustainability_report p.34

Co-authored 10-point action plan for the circular bioeconomy. Eliminating 70 million single-use plastic items per year from a respiratory therapy device.

sustainability_report p.43

Reports primary contribution to UN SDGs 3 (Good health), 5 (Gender equality), 8 (Decent work), 12 (Responsible consumption), 13 (Climate action), 17 (Partnership for goals).

sustainability_report p.9

Committed to zero carbon operations (sites and fleet) by 2025 without carbon credits, and carbon negative across entire value chain by 2030. $1 billion programme. Targets exceed SBTi 1.5°C pathway.

sustainability_report p.35

Water footprint was 3.44 million m³ in 2020, a 20% reduction from 2015 baseline.

sustainability_report p.40

Committed to 100% renewable electricity by 2025 (RE100), doubling energy productivity (EP100), and 100% electric vehicle fleet by 2025 (EV100).

sustainability_report p.37

Committed to ensuring racial equity in workplace and access to medicines, clinical trials and beyond. Founding partner of WEF Partnering for Racial Justice in Business.

sustainability_report p.52

Launched AZ Forest, a global initiative to plant 50 million trees worldwide by 2025 as nature-based solution. Over 337,000 trees planted in Indonesia and Australia in 2020.

sustainability_report p.37

Purchased goods and services represent 73.9% of Scope 3 emissions. Engaging suppliers to set Science Based Targets — in 2020, 4% of total procurement spend was with companies that have set or committed to SBTi targets. Sustainability Partner Guide and Framework drives supplier sustainability performance.

sustainability_report p.37

In 2020, 89% of electricity use was from renewable sources, with renewable imported electricity at 99.9% and 5.3GWh of on-site solar PV. Remaining 11% delivered by on-site CHP using fossil gas. Member of RE100, EP100, EV100, and Renewable Thermal Collaborative. Pursuing clean heat solutions including green gas and electrification of heat for UK/US portfolios.

sustainability_report p.37

One of only three companies worldwide on CDP Climate Change A List for five consecutive years; also on CDP Water Security A list for five consecutive years; also Supplier Engagement Leader Board.

sustainability_report p.7